Published DATE: Aug 5, 2022
SEATTLE – Curi Bio Inc., a leading developer of human stem cell-based platforms for therapeutic discovery, today announced a new distribution agreement and partnership with NEXEL, a leader in iPSC technology in Asia. The partnership positions NEXEL as the exclusive distributor and service contract provider for Curi Bio products and services in the Republic of Korea. Additionally, as part of this collaboration, Curi Bio and NEXEL plan to work together to develop and commercialize various disease cell models, drug screening assays, and contract research services for drug discovery and safety applications both within and outside Korea.
Curi Bio’s current suite of platforms and services are included as part of the exclusive distribution partnership, including Mantarray (3D engineered muscle tissue platform for contractility analysis), Pulse (high-throughput video analysis of contractility), NanoSurface Plates (structural maturation of 2D cardiac and skeletal muscle cultures), Cytostretcher (2D cell-stretching instruments), Nautilus (optical mapping of voltage and calcium), and customized research services, such as new assay and model development and phenotypic screening.
“At Curi Bio, our goal is to provide researchers with innovative human-relevant cells, systems, and data to accelerate the discovery of new medicines,” said Curi Bio CEO, Michael Cho. “By partnering with NEXEL, we aim to reliably provide drug developers in Korea access to market-leading platforms and services to improve the clinical translatability of their drug discovery and preclinical screening workflows.” Choong-seong Han, CEO of NEXEL also commented, “We are thrilled to establish this important and synergistic partnership with Curi Bio fulfilling both companies’ needs, and expanding our global reach to another level.”
With the new ISO/IEC 17025:2017 qualification by KOLAS, NEXEL seeks to expand the global in vitro efficacy and toxicity market. NEXEL possesses the ability to make high-quality iPSC-derived cells, including the best-selling Cardiosight-S ®, which provides consistent, precise, and accurate results for research users. NeXST Cardiac Safety Service, a novel cardiotoxicity screening method, aids collaborators to make efficient decisions regarding drug development. By adding Curi Bio’s expertise in next-generation iPSC platforms and services, NEXEL expects to rapidly expand the boundaries of cell & organoid-based toxicology testing.
Through these collaborations, Curi continues its goal to partner with leading pharma companies throughout the world to access its suite of market-leading platforms and develop safer, more effective human-relevant therapeutics. With costs to develop a single new medicine now exceeding Bn, the need for more human-relevant disease models to improve translational efficiency in the drug development process has never been greater.
About Curi Bio
Curi Bio’s preclinical discovery platform combines human stem cells, systems, and data to accelerate the discovery of new medicines. The Curi Engine is a comprehensive, bioengineered platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and AI/ML-enabled phenotypic screening data. Curi’s suite of human stem cell-based products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new drugs in development. By offering drug developers an integrated preclinical platform comprising highly predictive human stem cell models to generate clinically-relevant data, Curi is closing the gap between preclinical data and human results, accelerating the discovery and development of safer, more effective medicines.
For more information, please visit www.curibio.com
Founded in 2012, NEXEL is a biotechnology company commercializing "Korea's first" induced pluripotent stem cell (iPSC)-derived cell products. The company’s offerings include top-quality iPSC-derived cells such as the best-selling Cardiosight-S ® and iPSC-derived cardiomyocyte-based cardiac safety testing(NeXST). NEXEL partners with leading universities and research institutions worldwide to discover, develop and create solutions. NEXEL owns two drug pipelines including NP-011, an intravenous protein therapy targeting the treatment of NASH, STEMI, and IBD. The kick-off of the phase 1 experiment for MI started in Adelaide, Australia this July. The second pipeline, NPT-0025 is an early-stage peptide drug candidate targeting IPF and Glaucoma.
For more information, please visit www.nexel.co.kr